SK Bioscience Co Ltd (302440) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SK Bioscience Co Ltd (302440) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩20.65 Billion ≈ $14.00 Million USD) by net assets (₩2.07 Trillion ≈ $1.41 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review how financially flexible is SK Bioscience Co Ltd to assess the company's free cash flow relative to its total liabilities.
SK Bioscience Co Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see SK Bioscience Co Ltd (302440) total market value for the company's overall valuation and market capitalisation.
SK Bioscience Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SK Bioscience Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AVI LTD (UNSP.ADR)/5
F:IZ60
|
N/A |
|
King’s Town Bank
TW:2809
|
0.025x |
|
Domain Holdings Australia Ltd
AU:DHG
|
0.049x |
|
Chalet Hotels Limited
NSE:CHALET
|
0.125x |
|
Jiangsu Eazytec Co Ltd
SHG:688258
|
0.025x |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
0.078x |
|
Alpha Metallurgical Resources Inc
NYSE:AMR
|
0.032x |
|
Jiugui Liquor Co Ltd
SHE:000799
|
-0.028x |
Annual Cash Flow Conversion Efficiency for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of SK Bioscience Co Ltd from 2018 to 2024. View SK Bioscience Co Ltd share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩2.02 Trillion ≈ $1.37 Billion |
₩-128.02 Billion ≈ $-86.76 Million |
-0.063x | -467.52% |
| 2023-12-31 | ₩1.70 Trillion ≈ $1.15 Billion |
₩29.35 Billion ≈ $19.89 Million |
0.017x | +124.01% |
| 2022-12-31 | ₩1.74 Trillion ≈ $1.18 Billion |
₩-124.96 Billion ≈ $-84.68 Million |
-0.072x | -121.41% |
| 2021-12-31 | ₩1.60 Trillion ≈ $1.09 Billion |
₩536.59 Billion ≈ $363.64 Million |
0.335x | -26.47% |
| 2020-12-31 | ₩263.79 Billion ≈ $178.77 Million |
₩120.22 Billion ≈ $81.47 Million |
0.456x | +386.10% |
| 2019-12-31 | ₩232.73 Billion ≈ $157.72 Million |
₩21.82 Billion ≈ $14.79 Million |
0.094x | +32.58% |
| 2018-12-31 | ₩210.73 Billion ≈ $142.81 Million |
₩14.90 Billion ≈ $10.10 Million |
0.071x | -- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more